Advanced Therapies Week 2022 | Enhancing the therapeutic capacity of MSCs

Despite numerous clinical trials featuring mesenchymal stem cell (MSC)-based therapies, only a select few have reached clinical approval. Tony Ting, PhD, Bone Therapeutics SA, Gosselies, Belgium, describes strategies to professionalize MSCs. Expansion culture and differentiation of MSCs to promote bone healing in the ALLOB platform will hopefully unleash the full potential of MSCs. Dr Ting additionally comments on genetic manipulation of induced pluripotent stem cells (iPSCs) to professionalize MSCs, where iSPC-derived MSCs will lead to therapies with a consistent quality. This interview took place at Advanced Therapies Week 2022.